Dean W. Felsher

Stanford Medicine — United States

Medicine · Health Sciences

73h-index23.3kcitations383works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(47), Cancer, Hypoxia, and Metabolism(47), Cancer Genomics and Diagnostics(39), Ubiquitin and proteasome pathways(30), Cancer Research and Treatments(30)

Publications383 total

EcDNA-borne structural variants drive oncogenic fusion transcript amplification
Cell·2026· 1 citedOpen Access
Supplementary Figures from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
2025Open Access
Supplementary Tables from MYC Overexpression Drives Immune Evasion in Hepatocellular Carcinoma That Is Reversible through Restoration of Proinflammatory Macrophages
2025Open Access
Sex disparity in survival outcomes of advanced gastric adenocarcinoma
BJC Reports·2025Open Access
Targeting the MYC oncogene with a selective bi-steric mTORC1 inhibitor elicits tumor regression in MYC-driven cancers
Cell chemical biology·2025· 2 cited
Association of HER2 amplification or overexpression with overall survival in advanced upper gastrointestinal adenocarcinomas
BJC Reports·2025Open Access
eLife Assessment: The context-dependent epigenetic and organogenesis programs determine 3D vs. 2D cellular fitness of MYC-driven murine liver cancer cells
2025Open Access
eLife Assessment: The context-dependent epigenetic and organogenesis programs determine 3D vs. 2D cellular fitness of MYC-driven murine liver cancer cells
2025Open Access
Low-level shRNA Cytotoxicity Can Contribute to MYC-induced Hepatocellular Carcinoma in Adult Mice
Molecular Therapy·2025Open Access
Lactobacillus acidophilus potentiates oncolytic virotherapy through modulating gut microbiota homeostasis in hepatocellular carcinoma
Nature Communications·2025· 8 citedOpen Access
EcDNA-borne PVT1 fusion stabilizes oncogenic mRNAs
2025· 2 citedOpen Access
Prognostic and biological divergence of upper gastrointestinal adenocarcinomas.
Journal of Clinical Oncology·2025
eLife Assessment: The context-dependent epigenetic and organogenesis programs determine 3D vs. 2D cellular fitness of MYC-driven murine liver cancer cells
2025Open Access
MYC Inactivation Restores Immune Surveillance in a Transgenic Mouse Model of T-Cell Acute Lymphoblastic Lymphoma
Blood·2024Open Access
Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease
Nature Cancer·2024· 35 citedOpen Access
Abstract PO-037: Machine learning-enabled transomics identifies three therapeutic targets for MYC-driven diffuse large B cell lymphoma
Blood Cancer Discovery·2024
A big step for MYC-targeted therapies
Trends in cancer·2024· 3 citedOpen Access
Abstract LB005: Identification of novel targets for MYC-driven hepatocellular carcinoma via transomics
Cancer Research·2024
Abstract 4151: Development of a cancer-activated biologic imaging platform for early lung cancer diagnosis
Cancer Research·2024
Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma
Nature Communications·2024· 13 citedOpen Access
page 1 of 20Next →

Frequent Co-authors

Arvin M. Gouw(10), Stephanie C. Casey(8), Ling Tong(5), Qiwei Yang(5), Alice C. Fan(5), Chi V. Dang(5), Jan van Riggelen(4), Constadina Arvanitis(4), J. Michael Bishop(4), Amedeo Amedei(4), David I. Bellovin(4), Richard N. Zare(4), Virginie Baylot(3), Alper Yetil(3), Andrew M. Kopelman(3), Åsa Karlsson(3), Jianghong Rao(3), Pavan Bachireddy(3), Zachary E. Stine(3), Brian J. Altman(3)